Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

A broad and potent neutralization epitope in SARS-related coronaviruses
Meng Yuan, Xueyong Zhu, Wanting He, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 29
Open Access | Times Cited: 56
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
Kyle P. Martin, Christine Grimaldi, Rolf Grempler, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 35
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 6
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process
Silvia Crescioli, Shashidhar S. Jatiani, Leonard Moise
mAbs (2025) Vol. 17, Iss. 1
Open Access
Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning
Wenhao O. Ouyang, Timothy J.C. Tan, Ruipeng Lei, et al.
Science Advances (2022) Vol. 8, Iss. 47
Open Access | Times Cited: 26
Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages
Ling Li, Xixian Chen, Zuowei Wang, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 12, pp. e1011856-e1011856
Open Access | Times Cited: 15
Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study*
Rui Song, Gang Zeng, Jianxing Yu, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Insights into next generation sequencing guided antibody selection strategies
M. Frank Erasmus, Fortunato Ferrara, Sara D’Angelo, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
Aline Almeida-Oliveira, Diana Freire, A. Andrade, et al.
Journal of Pharmaceutical Innovation (2023) Vol. 18, Iss. 3, pp. 1194-1212
Open Access | Times Cited: 10
Microfluidic-assisted single-cell RNA sequencing facilitates the development of neutralizing monoclonal antibodies against SARS-CoV-2
Ziwei Wang, Amelia Siqi Huang, Lingfang Tang, et al.
Lab on a Chip (2024) Vol. 24, Iss. 4, pp. 642-657
Open Access | Times Cited: 2
Viral Epitope Scanning Reveals Correlation between Seasonal HCoVs and SARS-CoV-2 Antibody Responses among Cancer and Non-Cancer Patients
Salum J. Lidenge, Dicle Yalcin, Sydney J. Bennett, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 448-448
Open Access | Times Cited: 2
Predicting the risk of primary Sjögren's syndrome with key N7-methylguanosine-related genes: A novel XGBoost model
Hui Xie, Y. Deng, J. L. Li, et al.
Heliyon (2024) Vol. 10, Iss. 10, pp. e31307-e31307
Open Access | Times Cited: 2
Targeting SARS-CoV-2 and host cell receptor interactions
Siew Pheng Lim
Antiviral Research (2022) Vol. 210, pp. 105514-105514
Open Access | Times Cited: 14
Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection
Lindsay Wieczorek, Michelle Zemil, Mélanie Merbah, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Interface‐Guided Computational Protein Design Reveals Bebtelovimab‐Resistance Mutations in SARS‐CoV‐2 RBD: Correlation with Global Viral Genomes and Bebtelovimab‐Escape Mutations
Shweata Maurya, S Rajesh Kumar, Aditya K. Padhi
ChemistrySelect (2023) Vol. 8, Iss. 46
Closed Access | Times Cited: 6
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19
Arturo Casadevall, Scott A. McConnell, Daniele Focosi
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 8, pp. 787-797
Closed Access | Times Cited: 1
Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab
Т. V. Beketova, N. О. Levina, M. V. Dubinskaia, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 2, pp. 158-164
Open Access | Times Cited: 3
Effects of the COVID-19 pandemic: new approaches for accelerated delivery of gene to first-in-human CMC data for recombinant proteins
Hervé Broly, Jonathan Souquet, Alain Beck
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Riding the Wave: Unveiling the Conformational Waves from RBD of SARS-CoV-2 Spike Protein to ACE2
Nikhil Maroli
The Journal of Physical Chemistry B (2023) Vol. 127, Iss. 40, pp. 8525-8536
Closed Access | Times Cited: 3
Novel neutralizing chicken IgY antibodies targeting 17 potent conserved peptides identified by SARS-CoV-2 proteome microarray, and future prospects
Jin Li, Te Liang, Ailian Hei, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 5
An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV
Hailong Guo, Bomsoo Cho, Paul R. Hinton, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 2
Orally administered recombinant Lactobacillus expressing PEDV neutralizing antibody protects piglets against PEDV infection
Yu Sun, Wenqi Song, Chong Gao, et al.
International Journal of Biological Macromolecules (2024) Vol. 282, pp. 137006-137006
Closed Access
Structural Immunology of SARS‐CoV‐2
Meng Yuan, Ian A. Wilson
Immunological Reviews (2024)
Open Access
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19
Garyphallia Poulakou, Pierre‐Joseph Royer, Nikolay Evgeniev, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning
Wenhao O. Ouyang, Timothy J.C. Tan, Ruipeng Lei, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top